Daiichi Sankyo Co., Ltd.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT02685345
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02675491
- Locations
- π―π΅
National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
π―π΅Kinki University Hospital, Osaka, Japan
π―π΅National Cancer Center Hospital, Tokyo, Japan
Phase 1 Study of Quizartinib
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT02675478
An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT02669732
- Locations
- π―π΅
SOUSEIKAI Hakata Clinic, Hakata-ku, Fukuoka, Japan
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT02667483
- Locations
- π―π΅
Kobe University Hospital, Hyogo, Kobe-shi, Japan
π―π΅National Center of Neurology and Psychiatry, Tokyo, Kodaira-shi, Japan
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 368
- Registration Number
- NCT02628392
- Locations
- π―π΅
Heishinkai Medical Group Incorporated OCROM Clinic, Suita-shi, Osaka, Japan
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT02607280
- Locations
- π―π΅
Shonan Kamakura General Hospital, Kamakura-shi, Kanagawa, Japan
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 292
- Registration Number
- NCT02564900
- Locations
- π―π΅
Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan
πΊπΈMayo Clinic, Jacksonville, Florida, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
DS-5565 Phase III Study for Post-herpetic Neuralgia
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 765
- Registration Number
- NCT02318719
- Locations
- π―π΅
Medical Corporation Fujigaki Clinic, Oita, Japan
DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 854
- Registration Number
- NCT02318706
- Locations
- π―π΅
Saiki Central Hospital, Oita, Japan
Β© Copyright 2024. All Rights Reserved by MedPath